Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 2, 2020

Primary Completion Date

November 13, 2020

Study Completion Date

November 13, 2020

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

Emapalumab

I.v. infusion every third day

BIOLOGICAL

Anakinra

Daily i.v. infusion

Trial Locations (12)

11355

NewYork-Presbyterian Queens, Flushing

19140

Temple University Hospital, Philadelphia

55101

Regions hospital, Saint Paul

84108

University of Utah Health, Salt Lake City

07450

The Valley hospital, Ridgewood

Unknown

ASST Spedali Civili di Brescia Dipartimento di Reumatologia e Immunologia Clinica, Brescia

S.C. Malattie Infettive, Ospedale Galliera, Genova

Ospedale Maggiore Policlinico, Dipartimento di Anestesia-Rianimazione e Medicina di Urgenza, Milan

Dipartimento di Medicina - DIMED, Azienda Ospedale - Università Padova, Padua

Azienda Ospedaliero-Universitaria di Parma, Dipartimento di Malattie infettive ed epatologia, Parma

Ospedale Lazzaro Spallanzani, Dipartimento di Malattie Infettive ad alta Intensità di cura ed altamente contagiose,Ospedale Lazzaro Spallanzani, Roma

ASL Città di Torino, Unit of Infectious Diseases, Medicine, Rheumatology, Torino

Sponsors
All Listed Sponsors
lead

Swedish Orphan Biovitrum

INDUSTRY